20.500.12556/RUL-136108 Treatment response to SGLT2 inhibitors from clinical characteristics to genetic variations SGLT2 (sodium-glucose cotransporter 2) inhibitors are a new class of antihyperglycaemic drugs that act on the proximal tubules of the kidney. They have shown efficacy in the management of diabetes mellitus type 2 and their cardiovascular and renal safety have been extensively investigated and confirmed in clinical trials. However, inter-individual differences in response to treatment with SGLT2 inhibitors may present in everyday clinical practice, and good predictors of glycemic response and the risk for adverse events in an individual patient are lacking. As genetic variability of SGLT2 may influence the treatment response, pharmacogenetic information could support the choice of the most beneficial treatment strategy in an individual patient. This review focuses on the clinical and genetic factors that may influence the treatment response to SGLT2 inhibitors in type 2 diabetes patients with comorbid conditions. SGLT2 inhibitors cardiovascular safety renal safety genetic polymorphisms SGLT2 inhibitorji kardiovaskularna varnost nefrologija genetski polimorfizem true false true Angleški jezik Slovenski jezik Članek v reviji 2022-04-13 09:57:00 2022-04-13 09:57:01 2022-09-15 04:13:24 0000-00-00 00:00:00 2021 0 0 12 str. iss. 18, art. 9800 Vol. 22 2021 0000-00-00 Zaloznikova Objavljeno NiDoloceno 0000-00-00 0000-00-00 2021-01-01 616.379 1422-0067 10.3390/ijms22189800 77487107 ijms-22-09800.pdf ijms-22-09800.pdf 1 5B5B936DACB0FB8C3D59F98421452074 a3ed54963506b0246585c38f29cdc6124f29734886e48c5bee6b6053215c5c68 0876bd94-bb01-11ec-8aca-00155dcfd717 https://repozitorij.uni-lj.si/Dokument.php?lang=slv&id=155575 https://www.mdpi.com/1422-0067/22/18/9800 0 3fbcba4d-baff-11ec-8aca-00155dcfd717 https://repozitorij.uni-lj.si/Dokument.php?lang=slv&id=155574 Medicinska fakulteta 0 0 0